Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.77 |
| ▸ | APP | P05067 | 9/20 | 0.77 |
| ▸ | CTSD | P07339 | 2/20 | 0.50 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948088 | 0.87 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL9948620 | 0.87 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL18927139 | 0.85 | BACE1 (0.67) | BACE1APPCTSDBACE2KCNH2 | |
| SCHEMBL10270599 | 0.81 | BACE1 (0.78) | BACE1APP | |
| SCHEMBL9948456 | 0.81 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL9947877 | 0.81 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL18926394 | 0.80 | BACE1 (0.66) | BACE1APPBACE2 | |
| SCHEMBL9948169 | 0.78 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL9948016 | 0.78 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL18926487 | 0.76 | BACE1 (0.65) | BACE1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CTSD 50/4885 |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CTSD 50/4885 |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CTSD 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.